Biotech

CRSP·Healthcare·Biotech

CRISPR Therapeutics CAR-T: Inside Cathie Wood’s Next $60B Biotech Boom

Could CRISPR Therapeutics' overlooked CAR-T pipeline quietly revolutionize cancer treatment and catch Wall Street completely off guard?

5 days ago

MRNA·Healthcare·Biotech

ASML Stock Drops 6% as Weak Bookings Shadow Earnings Beat

Can ASML's dominant position in AI chipmaking offset a worrying slowdown in traditional semiconductor demand?

1 week ago

BIIB·Healthcare·Biotech

Biogen LEQEMBI Approval: Stock Plunges 8% Despite FDA Greenlight

Can Biogen's revolutionary new Alzheimer's treatments save the company's valuation, or is the massive market sell-off a warning sign for…

2 weeks ago

MRNA·Healthcare·Biotech

Moderna Forecast -8.2%: Plunge as $39 Target Alarms Bulls

Can Moderna’s pipeline story outweigh a brutal valuation reset, or is the latest sell-off warning investors not to chase the…

3 weeks ago

MRNA·Healthcare·Biotech

Moderna Flu Vaccine: FDA Briefing Sets Up Key Vote

Will Moderna Flu Vaccine finally clear the FDA hurdle, or is Wall Street getting ahead of itself again?

1 month ago

MRNA·Healthcare·Biotech

Moderna Restructuring +6.3% as FDA Momentum Builds

Can Moderna Restructuring turn an mRNA pioneer into a true multi-product biotech contender before its next major FDA test?

1 month ago

BNTX·Healthcare·Biotech

BioNTech Oncology Faces $1B Buyback Warning Before ASCO

Can BioNTech Oncology turn its huge cash pile into a real cancer breakthrough before investors lose patience?

2 months ago

REGN·Healthcare·Biotech

Regeneron Melanoma Trial: -11.5% Plunge After Phase 3 Shock

Can the Regeneron Melanoma Trial setback derail the biotech’s oncology growth story, or will upcoming data flip the narrative?

2 months ago

MRNA·Healthcare·Biotech

Moderna Hantavirus +12% Rally: Can The Surge Last?

Is the Moderna Hantavirus buzz really powering MRNA’s double-digit rally, or are traders simply chasing the next outbreak story?

3 months ago

AMGN·Healthcare·Biotech

Amgen Earnings -5.3% Plunge: Guidance Shock Despite Upgrade

Are the latest Amgen Earnings a buying opportunity after the stock’s sudden plunge, or a warning sign that growth is…

3 months ago